Table 1.
Summary of tumor responses in the RAG model.
| Tumor response | Control | Lenvatinib | Axitinib | PD-1 Ab | LEN+ PD-1 Ab | Axi+ PD-1 Ab |
|---|---|---|---|---|---|---|
| PD (≥30%) | 95% | 35% | 80% | 85% | 15% | 60% |
| SD (≥−50%, <30%) | 5% | 60% | 20% | 0% | 15% | 25% |
| PR (≥−95%, <−50%) | 0% | 5% | 0% | 5% | 20% | 5% |
| CR (<−95%) | 0% | 0% | 0% | 10% | 50% | 10% |
| Nonresponder (PD+SD) | 100% | 95% | 100% | 85% | 30% | 85% |
| Responder (PR+CR) | 0% | 5% | 0% | 15% | 70% | 15% |
| P (vs. LEN + PD-1 Ab) | <0.0001 | <0.0001 | <0.0001 | 0.0011 | — | 0.0011 |
Note: Tumor responses were defined as follows: complete response (CR), tumor volume (TV) decreased by more than 95%; partial response (PR), TV decreased by 50% to 95%; stable disease (SD), TV decreased by 30% to 50%; progressive disease (PD), TV not otherwise categorized. Nonresponders are mice categorized as having as PD and SD, and responders are those defined as having PR and CR. The difference in response rate (responders vs. nonresponders) between groups was analyzed by Fisher exact test.
Abbreviation: LEN, lenvatinib.